Allworth Financial LP Has $7.86 Million Position in Zoetis Inc. $ZTS

Allworth Financial LP boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 32.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 62,429 shares of the company’s stock after buying an additional 15,199 shares during the period. Allworth Financial LP’s holdings in Zoetis were worth $7,855,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in ZTS. Global Wealth Strategies & Associates acquired a new position in Zoetis in the 4th quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the third quarter worth $31,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the fourth quarter worth $30,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the fourth quarter worth $32,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of Zoetis in the fourth quarter worth $38,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ZTS shares. JPMorgan Chase & Co. lowered their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Bank of America raised their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average target price of $137.50.

Insider Transactions at Zoetis

In other news, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 11,650 shares of company stock worth $886,384 in the last quarter. Insiders own 0.22% of the company’s stock.

Zoetis Trading Down 1.8%

NYSE ZTS opened at $74.11 on Friday. The business’s fifty day moving average is $112.28 and its 200-day moving average is $120.94. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The stock has a market capitalization of $31.07 billion, a price-to-earnings ratio of 12.29, a PEG ratio of 1.23 and a beta of 0.87. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts predict that Zoetis Inc. will post 6.89 EPS for the current year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.